Sofia R. Gameiro, Ph.D.
- Center for Cancer Research
- National Cancer Institute
- Building 10, Room 5B46
- Bethesda, MD 20892
- 240-858-3439
- sofia.gameiro@nih.gov
RESEARCH SUMMARY
Dr. Gameiro is a Staff Scientist and Head of the Molecular Immunology Group of the Center for Immuno-Oncology, NCI. This group examines how emerging therapeutics can modulate the immune system to exert potent antitumor activity, with particular emphasis on how the mechanisms involved can be exploited to maximize antitumor activity in combination regimens with novel immunotherapies and other anticancer modalities.
Dr. Gameiro received her Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo, NY. Dr. Gameiro's research interests include immune modulation; tumor microenvironment; tumor immunology. The Molecular Immunology Group examines how emerging therapeutics can modulate the immune system to exert potent antitumor activity, with particular emphasis on how the mechanisms involved can be exploited to maximize antitumor activity in combination regimens with novel immunotherapies and other anticancer modalities. These studies form the rationale for novel hypothesis-driven clinical interventions.
Areas of Expertise
Research
Our research program is focused on identifying and exploiting immune mechanisms elicited by novel immunotherapeutics and emerging anticancer agents with the goal of maximizing antitumor efficacy in combination regimens. We are examining the mechanisms through which anticancer agents can reprogram the immunosuppressive tumor microenvironment to allow for efficient immunological control of tumor growth. We hypothesize that effective cancer control and long-term survival benefit can be attained by strengthening the patient’s own immune system through the combination of multiple immune modulating agents.
Publications
- Bibliography Link
- View Dr. Gameiro's PubMed Summary.
Functional and mechanistic advantage of the use of a bifunctional anti-PD-L1/IL-15 superagonist
Cooperative immune-mediated mechanisms of the HDAC inhibitor entinostat, an IL-15 superagonist, and a cancer vaccine effectively synergize as a novel cancer therapy
Biography
Sofia R. Gameiro, Ph.D.
Dr. Sofia Gameiro received her Ph.D. in Pharmaceutical Sciences from the State University of New York at Buffalo in 2008. She subsequently joined the NIH as a Postdoctoral Fellow in the Laboratory of Tumor Immunology and Biology, Center for Cancer Research, National Cancer Institute, and was appointed as a Staff Scientist in 2017. She is currently head of the Molecular Immunology Group of the Center for Immuno-Oncology's Translational Research area. Dr. Gameiro’s current research focuses on identifying and exploiting mechanisms through which anticancer agents can reprogram the immunosuppressive tumor microenvironment to allow for efficient immune-mediated elimination of cancer cells.
